Organized by:

FALK FOUNDATION e.V.
Leinenweberstr. 5
79108 Freiburg
Germany

Congress Department
Telephone: +49-761-1514-125
Telefax: +49-761-1514-359
E-Mail: symposia@falk-foundation-symposia.org
www.falk-foundation-symposia.org

Program
12 credit hours (CME) have been awarded for Symposium 218 by the European Union of Medical Specialists (UEMS).
Preface

Dear colleagues and friends,

I am delighted to welcome you to the first Symposium, organized by Falk Foundation e.V., in Mexico City on March 6 and 7, 2020. This will be the second Symposium held in Latin America after more than two decades. It is a great privilege to have this event in Mexico where the incidence and prevalence of Inflammatory Bowel Disease (IBD) has increased importantly in the last decade. Mexico City, capital of the country, lies at an altitude of more than 2,200 meters in the Anáhuac Valley, surrounded by mighty mountain ranges and two magnificent snow-covered volcanoes, Popocatépetl and Iztaccíhuatl. This city is one of the world’s largest cities, both in terms of population and area, most of the city’s best tourist attractions and popular things to do are in the historic city center, a 15-square-kilometer UNESCO World Heritage Site containing more than 1,400 important buildings from the 16th to 19th centuries, as well as several museums such as Frida Kahlo Museum, the National Museum of Anthropology, the Palace of Fine Arts and others.

The theme of this Symposium in Mexico City is “Current Challenges of Inflammatory Bowel Disease”. The linear program has seven selected sessions, structured around epidemiology, monitoring tools, conventional and biological treatment, new emerging therapeutic approaches, surgical issues and special situations focused on clinical practice with direct relevance to patient care, as well as poster presentations.

Our aims remain to provide an exciting academic program with latest and best scientific information and education in order to share and discuss the most relevant topics of IBD approach for improving outcomes and quality of life in patients with IBD.

Thanks to the generosity of Falk Foundation and all our international IBD experts for all time, effort and dedication in this important event.

On behalf of the organizing committee, Maria Abreu, Fernando Gomollon and Francisco Bosques, I extend a warm welcome to you all in Mexico City!

Yours sincerely,

Jesús Yamamoto-Furusho
Chair of the Organizing Committee
Current Challenges of Inflammatory Bowel Disease

March 6–7, 2020
Hyatt Regency Hotel
Mexico City, Mexico

Start of Registration:
Thursday, March 5, 2020
16.00 - 21.00 h
at the congress office

Setting Up of Poster Session:
Thursday, March 5, 2020
16.00 - 21.00 h

Congress Venue:
Hyatt Regency Hotel
Campos Elíseos 204
Polanco Chapultepec
11560 Mexico City
Mexico

Symposium 218 is organized by Falk Foundation e.V.

Scientific Organization:
Prof. Dr. Jesús K. Yamamoto-Furusho
Clinica de Enfermedad Inflamatoria Intestinal
Departamento de Gastroenterología
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
Segundo piso, Calle Vasco de Quiroga 15
Colonia Belisario Domínguez Sección XVI Delegación Tlalpan. C.P. 14080 Ciudad de México
Mexico
Telephone: +52-5555-733-418
Telefax: +52-5556-060-944
E-mail: kazuofurusho@hotmail.com

Scientific Co-Organization:
M.T. Abreu, Miami (USA)
F.J. Bosques Padilla, Monterrey (Mexico)
F. Gomollón, Zaragoza (Spain)

Official Language:
English
Translation into Spanish
Friday, March 6, 2020

9.00 Welcome and Introduction

J.K. Yamamoto-Furusho, Mexico City

Session I
Emerging epidemiology of IBD worldwide

Chair: M.T. Abreu, Miami; F.J. Bosques Padilla, Monterrey

9.10 The old world of Europe: Has the incidence and prevalence of IBD stabilized?

P. Munkholm, Copenhagen

9.35 How studying immigrants can edify the epidemiology of IBD

G. Kaplan, Calgary

10.00 Epidemiology of IBD in Asia

Z. Ran, Shanghai

10.25 Rising incidence of inflammatory bowel disease in Mexico and Latin America?

J.K. Yamamoto-Furusho, Mexico City

10.50 Coffee break with poster session

Session II
Monitoring tools in IBD

Chair: M. Duijvestein, Amsterdam; R. Panaccione, Calgary

11.20 Serological and fecal biomarkers

M.C. Dubinsky, New York

11.45 Chromoendoscopy vs. digital technology for the detection of lesions and dysplasia in UC patients

A.S. Cheifetz, Boston

12.10 What radiological tool is better in Crohn’s disease patients?

J. Rimola, Barcelona

12.35 Does histological remission matter - View of a pathologist also on neoplasia

M. Vieth, Bayreuth

13.00 Lunch break with poster session
Friday, March 6, 2020

Session III
Conventional treatment still useful in IBD?

Chair: B.E. Sands, New York; S. Schreiber, Kiel

14.30 Patient profile for the use of 5-ASA in IBD
A.H. Steinhart, Toronto

14.55 Topical vs. systemic steroids in IBD
A. Dignass, Frankfurt

15.20 Role of thiopurines and methotrexate in IBD
F. Carbonnel, Paris

15.45 Challenges in the management of severe ulcerative colitis
J.O. Lindsay, London

16.10 Coffee break with poster session

Session IV
Practical issues in the treatment of IBD with anti-TNF therapy

Chair: S. Ghosh, Birmingham; W.J. Sandborn, San Diego

16.40 Top-down vs. step-up approach
E.V. Loftus, Rochester

17.05 Empirical optimization vs. therapeutic drug monitoring
M.T. Abreu, Miami

17.30 Is anti-TNF therapy for ever?
M. Duijvestein, Amsterdam

17.55 Safety concerns of TNFα antagonists
S. Singh, San Diego

18.20 Networking with light refreshments
Saturday, March 7, 2020

Session V
Surgical issues in IBD

Chair: W.A. Bemelman, Amsterdam; A. D’Hoore, Leuven

9.00  Small bowel resection vs. stricturoplasty  W.A. Bemelman, Amsterdam


9.50  Role of mesenteric fact in the clinical course of CD  A. D’Hoore, Leuven

10.15 Management of refractory pouchitis  B. Shen, New York

10.40  Coffee break with poster session

Session VI
Challenges in IBD

Chair: F. Gomollón, Zaragoza; G. Rogler, Zurich

11.10  Management of psycho-social issues for IBD patients and their families  C.N. Bernstein, Winnipeg

11.35  The pediatric-adult transition: How to bridge the change  J. Martín de Carpi, Barcelona

12.00  Presentation of Poster Awards  M.T. Abreu, Miami

12.15  Telemedicine: The new medicine for IBD?  F. Gomollón, Zaragoza

12.40  Personalized medicine for the treatment of IBD  C. Fiocchi, Cleveland

13.05  Lunch break with poster session
Saturday, March 7, 2020

Session VII
New and emerging therapeutic approaches for IBD

Chair: J.O. Lindsay, London; E.V. Loftus, Rochester

14.05 What is the better patient profile for vedolizumab treatment? W.J. Sandborn, San Diego

14.30 Ustekinumab and other interleukin-23 inhibitors for inflammatory bowel disease B.E. Sands, New York

14.55 JAK inhibitors: A new kid in the block S. Ghosh, Birmingham

15.20 Future therapeutic targets in IBD S. Schreiber, Kiel

15.45 Coffee break with poster session

Session VIII
Special situations in IBD

Chair: C.N. Bernstein, Winnipeg; S. Singh, San Diego

16.15 Sexual dysfunction and pregnancy C.J. van der Woude, Rotterdam

16.40 Impact of infections in the course and treatment of patients with IBD G. Rogler, Zurich

17.05 IBD a systemic disease: Extraintestinal manifestations R. Panaccione, Calgary

17.30 Closing Remarks J.K. Yamamoto-Furusho, Mexico City
Poster Abstracts

1. Hematological scales as indicators of the exacerbation in ulcerative colitis patients – A single-center experience
   H. Cichoż-Lach, A. Michalak, K. Laskowska, P. Radwan, B. Kasztelan-Szczerbińska (Lublin, PL)

2. Clinical value of lactulose breath test in diagnosis of small intestinal bacterial overgrowth in ulcerative colitis and irritable bowel syndrome
   Y. Cortés Aguilar, G. Priego Figueroa, F. Ruíz Montenegro Cortés, J. Valenzuela Pérez, H. Gómez Rodríguez, C. Jaramillo Buendia, E. Rodríguez Magaña (Guadalajara, MX)

3. Faecal microbiota transplantation: An emerging treatment for ulcerative colitis
   A. Cunningham, M. Hitchings, D. Harris (Swansea, GB)

   O. Daboussi, J. Boucher, A. Herber (Le Coudray, FR)

5. Prevalence and risk factors of malnutrition in Crohn’s disease patients
   O. Daboussi, M. Luwawu, A. Herber (Le Coudray, FR)

6. CONUT score: A promising tool for nutritional assessment and severity evaluation in ulcerative colitis patients
   J. de León Rendón, N. Gracida Mancilla, R. López Pérez, Y. Gutiérrez Grobe, B. Jiménez Bobadilla, J. Villanueva Herrero (Mexico City, MX)

7. Neutrophil/lymphocyte ratio as a severity predictor in ulcerative colitis
   J. de León Rendón, N. Gracida Mancilla, R. López Pérez, Y. Gutiérrez Grobe, B. Jiménez Bobadilla, J. Villanueva Herrero (Mexico City, MX)

8. Gene expression profiling of mediators associated to the inflammatory pathways in the intestinal tissue from patients with ulcerative colitis
   G. Fonseca-Camarillo, E. Iturriaga-Goyon, R. Barredo-Zuñiga, L. Salazar-Salas, A. Peredo-Escárcega, J. Yamamoto-Furusho (Mexico City, MX)

9. Intestinal expression of interleukin-27 by immune cells in patients with inflammatory bowel disease
   G. Fonseca-Camarillo, J. Furuzawa-Carballeda, J. Yamamoto-Furusho (Mexico City, MX)

10. Overexpression of metalloproteinases-10 and -23 (MMP10, MMP23B) in inflammatory bowel disease
    G. Fonseca-Camarillo, J. Furuzawa-Carballeda, J. Yamamoto-Furusho (Mexico City, MX)

11. Transcriptome of intestinal epithelial barrier genes in the colonic mucosa from patients with ulcerative colitis
    G. Fonseca-Camarillo, E. Iturriaga-Goyón, J. Yamamoto Furusho (Mexico City, MX)
12. Defensins alpha 5 and 6 are up-regulated in the colonic mucosa from patients with ulcerative colitis and are associated with histological activity
   G. Fonseca-Camarillo, J. Yamamoto-Furusho (Mexico City, MX)

13. Characterization of TOB/BTG family proteins in intestinal tissue of patients with inflammatory bowel disease and controls
   G. Fonseca-Camarillo, G. Fonseca-Camarillo, B. Martínez Benítez, J. Furuzawa Carballeda, R. Barreto Zuñiga, Á. Priego Ranero, J. Yamamoto Furusho (Mexico City, MX)

14. A comprehensive, multiomic diet intervention study comparing a low fat, high fiber diet to an idealized standard American diet in ulcerative colitis patients

15. Concerns of patients with inflammatory bowel disease and perception of risks and benefits of medical, surgical and alternative therapies
   F. Gomollón, P. Belanche, C. Gargallo Puyuelo, E. Alfambra, M. Arroyo, A. Lué (Zaragoza, Huesca, ES)

16. Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis-related fibrosis in patients with inflammatory bowel disease
   F. Gomollón, P. Alós, C. Gargallo Puyuelo, E. Alfambra, M. Arroyo (Zaragoza, ES)

17. Risk of anxiety, depression and poor quality of life in patients with inflammatory bowel disease
   F. Gomollón, P. Belanche, C. Gargallo Puyuelo, E. Alfambra, M. Arroyo, A. Lué (Zaragoza, Huesca, ES)

18. The relationship between undernutrition and anemia in ulcerative colitis patients: Cross-sectional study results
   S. Ivanov, Y. Uspenskiy, Y. Fominikh, I. Khoroshilov (St. Petersburg, RU)

19. Anemia in patients with intestinal inflammatory disease in a reference center in Medellin-Colombia

20. Characterization of the intestinal inflammatory disease in Colombia: Results of a national registry

21. Cross-sectional study using real world data on the active detection of patients with inflammatory bowel disease in Kazakhstan
22. Administration of biosimilar drugs to IBD patients
M. Konecny (Olomouc, CZ)

23. Deviations in platelet and red blood cell indices in ulcerative colitis patients treated with vedolizumab
A. Michalak, H. Cichoż-Lach, K. Laskowska, P. Radwan, B. Kasztelan-Szczepińska (Lublin, PL)

24. Quality of life in patients with inflammatory bowel disease: About a Tunisian monocentric study
S. Nsibi, R. Ennaifer, M. Ayari, B. Bouchabou, F. Ben Farhat, H. Ben Nejma (La Marsa, TN)

25. Phenotypic analysis of patients with inflammatory bowel disease: 23-year data of a center in a South American country
C. Paez Cancelado, B. Mendoza De Molano, R. García Duperly, A. Rey Rubiano, R. López Panqueva, E. Londoño Schimmer, J. Padrón Mercado, M. Mejia Arango, R. Vallejo Madroñero, J. Park (Bogota, CO)

26. Epidemiological and clinical characterization of inflammatory bowel disease (IBD) in Latin America and the Caribbean: A multicenter study (EPI-LATAM IBD) from the Pan American Crohn’s and Colitis Organization (PANCCO)
N. Parra-Holguín, J. Yamamoto-Furusho, E. Grupo-Colombiano, F. Bosques-Padilla, G. Veitia-Velásquez, E. Torres, F. Piñol-Jiménez, S. Bautista, A. Frias-Santana, K. Villa-Ovalles, G. Otoya-Moreno, B. Lado Vergara; Study-Group EPI-LATAM (Mexico City, Monterrey, MX; Bogota, CO; Caracas, VE; San Juan, PR; Habana, CU; Santo Domingo, DO; Lima, PE; Montevideo, UY)

27. Experience on the use of methotrexate in Crohn’s disease from a third care level hospital
N. Parra-Holguín, J. Yamamoto-Furusho (Mexico City, MX)

28. High frequency of primary hypothyroidism in Mexican patients with inflammatory bowel disease
N. Parra-Holguín, J. Yamamoto-Furusho (Mexico City, MX)

29. Impact of fatigue on the quality of life and sleep in Mexican patients with inflammatory bowel disease
N. Parra-Holguín, J. Yamamoto-Furusho, A. Fresán-Orellana (Mexico City, MX)
30. Effect of vedolizumab on extraintestinal manifestations of inflammatory bowel diseases  
   G. Piovezani Ramos, N. McDonald, L. Janssens, B. Al Bawardy, J. Davis, E. Loftus  
   (Rochester, New Haven, US)

31. Ulcerative colitis with sudden exacerbation and the relationship with Clostridioides difficile infection: An observational study  
   S. Scharrer-Cabello, D. Benavides-Salgado, J. Guerrero-Tamez, C. Alfaro-Rivera,  
   E. Yin-Bañuelos, B. González-Gómez, J. Jáquez-Quintana, F. Bosques-Padilla  
   (Monterrey, Baja California, MX)

32. The relationship between the duration of the diagnosis of IBD and clinical features of the illness  
   M. Skalinskaya, E. Skazyvaeva, I. Bakulin, A. Vardanyan, K. Ivanova, I. Rasmagina,  
   D. Komarova (St. Petersburg, Moscow, RU)

33. The frequency of joints manifestations of inflammatory bowel disease in the practice of a rheumatologist  
   O. Sulima, V. Sulyma (Dnipro, UA)

34. The results of complex treatment of patients with inflammatory bowel diseases using 5-aminosalicylic acid (5-ASA) drugs, corticosteroids, immunosuppressants and biological therapy  
   V. Sulyma, Y. Bereznytskyy, V. Gaponov, S. Malinovskyj, I. Yuschenko, O. Sulima  
   (Dnipro, UA)

35. The presence of pancolitis was associated with the development of any type of neoplasia in patients with ulcerative colitis  
   J. Toledo, J. Yamamoto-Furusho (Mexico City, MX)

36. Frequency of pharmacologic intolerance in Mexican patients with ulcerative colitis  
   J. Toledo, J. Yamamoto-Furusho (Mexico City, MX)

37. Socioeconomic characteristics are associated with clinical course in Mexican patients with ulcerative colitis  
   J. Toledo, J. Yamamoto-Furusho (Mexico City, MX)

38. TRPV4 protein expression is low in Mexican patients with severe ulcerative colitis  
   J. Toledo, J. Yamamoto-Furusho (Mexico City, MX)

39. The multidrug resistant proteins (MRPs) in ulcerative colitis (UC)  
   M. Villeda-Ramírez, G. Fonseca-Camarillo, J. Yamamoto-Furusho  
   (Mexico City, MX)

40. Global hospitalization trends for Crohn’s disease and ulcerative colitis: Systematic review with temporal analyses  
   J. Windsor, M. Buie, S. Coward, R. Gearry, T. Hansen, J. King, P. Kotze, C. Ma,  
   S. Ng, N. Panaccione, R. Panaccione, J. Quan, F. Underwood, G. Kaplan  
   (Calgary, CA; Christchurch, NZ; Curitiba, BR; Sha Tin, HK)
41. The penetrance of IBD through a population: Comparison of the relative global incidence and prevalence of ulcerative colitis and Crohn’s disease
   J. Windsor, M. Buie, S. Coward, R. Gearry, T. Hansen, J. King, P. Kotze, C. Ma, S. Ng, N. Panaccione, R. Panaccione, J. Quan, F. Underwood, G. Kaplan (Calgary, CA; Christchurch, NZ; Curitiba, BR; Sha Tin, HK)

42. Diagnostic utility of the neutrophil-platelet ratio (NeuPla ratio) as a marker of activity in patients with ulcerative colitis
   J. Yamamoto-Furusho, E. Mendieta-Escalante (Mexico City, MX)

43. High correlation between fecal calprotectin and a Novel Integral Index for evaluating disease activity in ulcerative colitis patients
   J. Yamamoto-Furusho, E. Mendieta-Escalante (Mexico City, MX)
List of Speakers, Moderators and Scientific Organizers

Maria T. Abreu, M.D.
Professor of Medicine
University of Miami
Gautier Medical Research Building, Room #510
1011 NW 15th Street
Miami, FL 33136
USA
mabreu1@med.miami.edu

Prof. Dr. Willem A. Bemelman
Department of Surgery
Tytgat Institute for Liver & Intestinal Research
University van Amsterdam
Meibergdreef 9
1105 AZ Amsterdam
The Netherlands
w.a.bemelman@amc.uva.nl

Dr. Charles N. Bernstein
Department of Gastroenterology
University of Manitoba
804 F-175 McDermot Avenue
Winnipeg, MB R3E 3P4
Canada
charles.bernstein@med.umanitoba.ca

Dr. Francisco J. Bosques Padilla
Servicio de Gastroenterología
Hospital Universitario
Dr. José Eleuterio González
Universidad Autónoma de Nuevo León
64710 Monterrey, N.L.
Mexico
fbosques58@hotmail.com

Prof. Dr. Franck Carbonnel
Service d’Hépatogastroentérologie
Hôpital de Bicêtre
78 rue du Général Leclerc
94275 Le Kremlin Bicêtre
France
franck.carbonnel@bct.aphp.fr

Adam S. Cheifetz, M.D.
Professor of Medicine
Harvard School of Medicine
Center for Inflammatory Bowel Disease
Beth Israel Deaconess Medical Center
330 Brookline Ave
Rabb 425
Boston, MA 02215-5400
USA
acheifet@bidmc.harvard.edu

Prof. Dr. André D’Hoore
Department of Abdominal Surgery
University Hospital Leuven
Herestraat 49
3000 Leuven
Belgium
andre.dhoore@uzleuven.be

Prof. Dr. Axel Dignass
Medizinische Klinik I
AGAPLESION
Markus Krankenhaus
Wilhelm-Epstein-Str. 4
60431 Frankfurt
Germany
axel.dignass@fdk.info

Marla C. Dubinsky, M.D.
Professor of Pediatrics
The Susan & Leonard Feinstein IBD Clinical Center
Suite 1165W
17 East 102nd Street, 5th Floor
New York, NY 10029
USA
marla.dubinsky@mssm.edu

Dr. Marjolijn Duijvestein
Department of Gastroenterology and Hepatology (Room PK 2 x 140)
Amsterdam UMC
De Boelelaan 1117
1081 HV Amsterdam
The Netherlands
m.duijvestein@amsterdamumc.nl
Claudio Fiocchi, M.D.
Professor of Medicine
Department of Inflammation & Immunity
Cleveland Clinic
9500 Euclid Avenue
Cleveland, OH 44195
USA
fiocchc@ccf.org

Edward V. Loftus, M.D.
Professor of Medicine
Division of Gastroenterology and Hepatology
Mayo Clinic
200 First Street SW
Rochester, MN 55905
USA
loftus.edward@mayo.edu

Prof. Dr. Subrata Ghosh
Institute of Translational Medicine
University of Birmingham
Birmingham B15 2TT
Great Britain
ghoshs@bham.ac.uk

Javier Martín de Carpi, M.D., Ph.D.
Department of Gastroenterology, Hepatology and Nutrition
Hospital Sant Joan de Déu Barcelona
Passeig de Sant Joan de Déu, 2
08950 Esplugues de Llobregat, Barcelona
Spain
javiermartin@sjdhospitalbarcelona.org

Prof. Dr. Fernando Gomollón
IBD Unit
Hospital Clinico Universitario “Losano Blesa”
Facultad de Medicina
Fundación del Instituto de Investigación Sanitaria de Aragón (IIS Aragón)
Avenida San Juan Bosco 15
50009 Zaragoza
Spain
fgomollon@gmail.com

Prof. Dr. Gilaad Kaplan
Division of Gastroenterology and Hepatology
Inflammatory Bowel Disease Clinic
Cumming School of Medicine
University of Calgary
Teaching Research and Wellness Building
Room 6D30, 3280 Hospital Drive NW
Calgary, AB T2N 4Z6
Canada
ggkaplan@ucalgary.ca

Prof. Dr. Pia Munkholm
Department of Gastroenterology
North Zealand University Hospital
Frederikssundsvej 30
3600 Frederikssund
Denmark
pia.munkholm@regionh.dk

Prof. Dr. Remo Panaccione
Inflammatory Bowel Disease Clinic
Cumming School of Medicine
University of Calgary
Teaching Research and Wellness Building
Room 6D30, 3280 Hospital Drive NW
Calgary, AB T2N 4Z6
Canada
rpanacci@ucalgary.ca

Prof. Dr. James O. Lindsay
Consultant Gastroenterologist
The Royal London Hospital
Whitechapel
London E1 1BB
Great Britain
james.lindsay@bartshealth.nhs.uk

Prof. Dr. Zhihua Ran
Department of Gastroenterology
Renji Hospital
Shanghai Jiaotong University
160 Pu Jian Rd., Pudong Distr.
200001 Shanghai
China
zhihuaran@vip.163.com

Feza Remzi, M.D.
Professor of Surgery
Inflammatory Bowel Disease Center
240 East 38th Street, 23rd Floor
New York, NY 10016
USA
feza.remzi@nyulangone.org
Congress Office
During Symposium 218

Congress Office Telephone: +49-175-7795-327

Opening Hours:
Thursday, March 5, 2020 16.00 – 21.00 h
Friday, March 6, 2020 8.00 – 18.30 h
Saturday, March 7, 2020 8.30 – 17.45 h

Congress Venue:
Hyatt Regency Hotel
Campos Elíseos 204
Polanco Chapultepec
11560 Mexico City
Mexico

Congress Fees
Scientific Program of Symposium 218 EUR 200
Students (copy of student ID required) EUR 100

***OR***
Day Ticket EUR 120
Students (copy of student ID required) EUR 60

The congress fees include:
- Pre-Opening and Welcome on Thursday, March 5, 2020
- Refreshments during coffee breaks
- Lunch on Friday, March 6 and on Saturday, March 7, 2020
- Networking with light refreshments on Friday, March 6, 2020
- A copy of the abstract volume
- A copy of the final program
Admission to Scientific Program

For admission to scientific events your name badge should be clearly visible. Accompanying persons are not permitted during the conference at any time.

Airport

Hyatt Regency Hotel is located in the upscale Polanco neighborhood, near Paseo de la Reforma and Chapultepec Park.

The distance between the airport and the hotel is around 17 kilometers and a car ride will take approximately 40 minutes.

Travelling by taxi is the best way to get to and from Mexico City Airport. It is strongly recommended to pick up an authorized taxi and avoid rides offered by non-authorized drivers.

Taxi ranks are located at the entrance of both terminals: Terminal 1 and Terminal 2 (international and domestic).

Only taxis by SCT Secretaría de Comunicaciones y Transportes are authorized to provide service at the airport. Currently the following taxi companies offering service at Mexico Airport (MEX): Porto Taxi, Sitio 300, Nueva Imagen, Excelencia, Confort and Yellow Cab.

You can purchase your ticket at the booths near the arrival gates in the walkway area. You can also use Uber, which is safe as well.

Further information can be found under: https://www.mexico-airport.com/taxi.php
Or ask the concierge of the hotel to organize your transfer.

Conflicts of Interest

Members of the scientific committee declare the following potential conflicts of interest: M.T. Abreu: Prometheus, Takeda, Eli Lilly, Pfizer, AbbVie, Janssen, Focus Medical Communications, Celgene, Shire; F.J. Bosques Padilla: AbbVie, Janssen, Takeda; F. Gomollón: MSD, AbbVie, Janssen, Tillots, Takeda; J.K. Yamamoto-Furusho: AbbVie, Alfasigma, Almiral, Bristol Myers Squibb, Celltrion, Danone, Farmasa, Ferring, Grunenthal, Janssen, Pfizer, Takeda.
International Symposia and Workshops

Scientific Dialogue in the Interest of Therapeutic Progress

Workshop
Primary Liver Cancer – Emerging Concepts and Novel Treatments
Mainz, Germany
February 13–14, 2020

Symposium 218
Current Challenges of Inflammatory Bowel Disease
Mexico City, Mexico
March 6–7, 2020

Workshop
Microscopic Colitis – New Insights and Recommendations
Copenhagen, Denmark
May 21, 2020

Symposium 219
IBD-Patients – In the Center of Care
Copenhagen, Denmark
May 22–23, 2020

Symposium 220
XXVI International Bile Acid Meeting: Bile Acids in Health and Disease 2020
Amsterdam, The Netherlands
July 10–11, 2020

Symposium 221
IBD Management in the New Decade: Old Myths and New Realities
Athens, Greece
October 2–3, 2020

Symposium 222
Eosinophilic Esophagitis – Advanced Science for Everyday Challenges in Clinical Practice
Zurich, Switzerland
November 20–21, 2020

FALK FOUNDATION e.V.
Leinenweberstr. 5
79108 Freiburg
Germany

Congress Department
Tel.: +49-761-1514-125
Fax: +49-761-1514-359
E-Mail: symposia@falk-foundation-symposia.org
www.falk-foundation-symposia.org

2020
Current Challenges of Inflammatory Bowel Disease

March 6–7, 2020
Hyatt Regency Hotel
Mexico City, Mexico

Organized by:
FALK FOUNDATION e.V.
Leinenweberstr. 5
79108 Freiburg
Germany

Congress Department
Telephone: +49-761-1514-125
Telefax: +49-761-1514-359
E-Mail: symposia@falk-foundation-symposia.org
www.falk-foundation-symposia.org

Program